Table 1.
Demographic and clinical characteristics of the cohort.
| Total (n = 60) | mRNA-based vaccines (mRNA-1273/BNT162b2) (n = 51) | Vector-based vaccines (ChAdOx1 nCoV-19Ad26.COV2-S) (n = 9) | p-value | |
|---|---|---|---|---|
| Demographics | ||||
| Age, years | 65.4 [54–75] | 66 [51–75] | 64 [58–73] | 0.99 |
| Male sex, n (%) | 38 [63.3%] | 33 [64.7%] | 5 [55.6%] | 0.71 |
| Dry weight, kg | 76 [64–89.5] | 75 [64–89] | 84 [54–92] | 0.81 |
| Body mass index, kg/m2 | 26.1 [22–29] | 26.0 [22–28] | 27.6 [20−1] | 0.88 |
| Comorbidities | ||||
| Hypertension, n (%) | 54 (90%) | 46 (90.2%) | 8 (88.9%) | 1.0 |
| Diabetes mellitus, n (%) | 21 (35%) | 18 (35.3%) | 3 (33.3%) | 1.0 |
| Coronary artery disease, n (%) | 30 (50%) | 25 (49%) | 5 (55.6%) | 1.0 |
| History of stroke, n (%) | 7 (11.7%) | 5 (9.8%) | 2 (22.2%) | 0.28 |
| Immunosuppressive therapy, n (%) | 7 (12.5%) | 5 (9.8%) | 2 (22.2%) | 0.28 |
| Cause of kidney failure, n (%) | 0.91 | |||
| Nephrosclerosis | 10 (16.7%) | 9 (17.6%) | 1 (11.1%) | |
| Diabetic nephropathy/nephrosclerosis | 12 (20%) | 10 (19.6%) | 2 (22.2%) | |
| Cardiorenal syndrome | 10 (16.7%) | 9 (17.6%) | 1 (11.1%) | |
| Glomerulonephritis | 13 (21.7%) | 10 (19.6%) | 3 (33.3%) | |
| Interstitial nephritis | 3 (5%) | 3 (5.9%) | – | |
| ADPKD | 4 (6.7%) | 4 (7.8%) | – | |
| Cancer | 5 (8.3%) | 4 (7.8%) | 1 (11.1%) | |
| Unknown | 3 (5%) | 2 (3.9%) | 1 (11.1%) | |
| Dialysis data | ||||
| Dialysis modality, n (%) | ||||
| Hemodialysis | 53 (88.3%) | 44 (86.3%) | 9 (100%) | 0.58 |
| Peritoneal dialysis | 7 (11.7%) | 7 (13.7%) | – | N/A |
| Dialysis vintage, months | 32.5 [15–49] | 35.0 [15.0–50.0] | 26.0 [6.5–34.0] | 0.16 |
| Kt/V | 1.6 [1.4–1.7] | 1.6 [1.4–1.7] | 1.4 [1.3–1.6] | 0.11 |
| Hemodialysis | 1.6 [1.4–1.7] | 1.6 [1.4–1.7] | 1.4 [1.3–1.6] | |
| Peritoneal dialysis | 2.4 [1.6–3.5] | 2.4 [1.7–2.9] | – | |
| Baseline clinical data | ||||
| Leucocyte count, g/L | 6.8 [4.8–8.3] | 7.0 [5.2–8.4] | 5.0 [4.4–7.3] | 0.34 |
| Differential count, g/L | ||||
| Total neutrophils | 4.4 [2.9–6.3] | 4.7 [2.8–6.5] | 3.6 [2.9–5.2] | 0.46 |
| Total lymphocytes | 1.2 [0.8–1.5] | 1.2 [0.9–1.5] | 1.1 [0.7–1.4] | 0.62 |
| Total basophils | 0.03 [0.02–0.04] | 0.02 [0.01–0.04] | 0.03 [0.02–0.03] | 0.87 |
| Total monocytes | 0.6 [0.5–0.8] | 0.6 [0.5–0.8] | 0.6 [0.4–0.7] | 0.70 |
| Total eosinophils | 0.2 [0.1–0.3] | 0.2 [0.1–0.3] | 0.3 [0.1–0.4] | 0.48 |
| Hemoglobin, g/dL | 10.8 [10.3–11.4] | 10.9 [10.4–11.4] | 10.5 [9.8–11.8] | 0.44 |
| Serum creatinine, mg/dLa | 7.0 [5.2–8.7] | 6.9 [5.5–8.9] | 7.6 [4.4–8.6] | 1.0 |
| Urea, mg/dLb | 120 [97–135] | 120 [110–136] | 85 [79–134] | 0.32 |
| Phosphate, mmol/L | 1.7 [1.4–1.9] | 1.8 [1.4–1.9] | 1.4 [1.3–1.9] | 0.44 |
| Parathyroid hormone, pg/mL | 299 [207–400] | 315 [214–413] | 280 [80–314] | 0.19 |
| Albumin, g/dL | 40.4 [38.2–42.5] | 40.1 [38.0–42.2] | 42.3 [40.9–42.7] | 0.12 |
| C-reactive protein, mg/L | 9.8 [2.2–20.2] | 10.2 [2.3–20.0] | 2.7 [0.8–25.0] | 0.74 |
| Total IgG, g/L | 10.8 [7.3–14.0] | 10.5 [7.3–14.0] | 10.9 [6.8–14.0] | 0.94 |
| IL-6, μg/L | 10.0 [10.0–11.5] | 10.0 [10.0–11.5] | 10.0 [10.0–13.6] | 1.0 |
| Soluble IL-2 receptor, U/mL | 1284 [873–1864] | 1284 [873–1927] | 1571 [1001–1844] | 0.71 |
| Ferritin, μg/L | 228 [82–542] | 214 [76–479] | 523 [108–916] | 0.17 |
Values are the median [interquartile range], or n (%).
ADPKD, autosomal dominant polycystic kidney disease; IgG, immunoglobulin G; IL-2, interleukin-2; IL-6, interleukin-6.
a
To convert the values for serum creatinine to μmol/L, multiply by 88.4.
b
To convert the values for urea to blood urea nitrogen, multiply by 0.467.